Skip to main content
AI-generated market analysis. Not investment advice. Methodology →

News Stream

Search headlines
manilatimes.net · Neutral · 5h ago

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months...

← Previous Page 3 of 3
{ this.currentMessage = (this.currentMessage + 1) % this.messages.length; }, 2200); }, stop() { if (this.rotator) { clearInterval(this.rotator); this.rotator = null; } }, show() { this.open = true; this.start(); }, hide() { this.open = false; this.stop(); }, }" x-init="if (open) start();" @page-loader-show.window="show()" @page-loader-hide.window="hide()" class="page-loader" :class="open ? 'is-visible' : ''" x-cloak aria-live="polite" aria-busy="true">